Your browser is no longer supported. Please, upgrade your browser.
Settings
ARQL ArQule, Inc. daily Stock Chart
ARQL [NASD]
ArQule, Inc.
Index- P/E- EPS (ttm)-0.17 Insider Own1.10% Shs Outstand107.86M Perf Week4.49%
Market Cap1.08B Forward P/E- EPS next Y-0.34 Insider Trans0.00% Shs Float107.36M Perf Month36.38%
Income-19.20M PEG- EPS next Q-0.10 Inst Own80.60% Short Float8.10% Perf Quarter101.81%
Sales23.00M P/S46.94 EPS this Y60.00% Inst Trans-0.34% Short Ratio3.22 Perf Half Y297.22%
Book/sh0.65 P/B15.40 EPS next Y15.80% ROA-20.90% Target Price9.44 Perf Year113.43%
Cash/sh0.85 P/C11.71 EPS next 5Y8.00% ROE-29.10% 52W Range2.23 - 10.51 Perf YTD261.37%
Dividend- P/FCF- EPS past 5Y16.90% ROI-14.60% 52W High-4.76% Beta2.18
Dividend %- Quick Ratio6.50 Sales past 5Y10.10% Gross Margin- 52W Low348.88% ATR0.71
Employees36 Current Ratio6.50 Sales Q/Q-68.30% Oper. Margin-87.70% RSI (14)70.68 Volatility6.98% 8.54%
OptionableYes Debt/Eq0.21 EPS Q/Q-25.60% Profit Margin-83.70% Rel Volume1.61 Prev Close10.49
ShortableYes LT Debt/Eq0.17 EarningsJul 31 BMO Payout- Avg Volume2.70M Price10.01
Recom1.70 SMA2030.52% SMA5045.09% SMA200108.34% Volume4,350,513 Change-4.58%
Apr-11-19Initiated RBC Capital Mkts Outperform $9
Jun-18-18Reiterated Needham Buy $6 → $7
May-08-18Reiterated Needham Buy $5 → $6
Apr-05-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-22-18Initiated ROTH Capital Buy $5
Feb-02-18Initiated B. Riley FBR, Inc. Buy $3
Dec-14-17Upgrade Needham Hold → Buy $5
Dec-21-15Upgrade RBC Capital Mkts Sector Perform → Outperform $4 → $5
Dec-09-15Resumed Leerink Partners Mkt Perform
May-12-14Reiterated MLV & Co Hold $3 → $1.75
May-24-13Reiterated MLV & Co Hold $2.25 → $3
Jan-14-13Downgrade MLV & Co Buy → Hold $4 → $2.25
Oct-02-12Downgrade Needham Buy → Hold
Sep-12-12Initiated Burrill Institutional Research Mkt Outperform $10
Jul-30-12Initiated Needham Buy
Mar-15-12Initiated Stifel Nicolaus Buy $13
Jan-31-12Initiated RBC Capital Mkts Outperform $11
May-26-11Initiated Global Hunter Securities Accumulate $11
Apr-01-10Reiterated Mehta Partners Outperform $5 → $9
Oct-13-09Upgrade UBS Sell → Buy
Jun-24-19 04:37PM  ArQule Announces Commencement of Proposed Public Offering of Common Stock Business Wire
01:27PM  Did Hedge Funds Drop The Ball On ArQule, Inc. (ARQL) ? Insider Monkey
Jun-18-19 04:01PM  ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 Business Wire
07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
Jun-17-19 03:22PM  Biotech ETFs Are Breaking Out on Pfizers Array Biopharma Deal ETF Trends +16.83%
03:21PM  ArQule Hits 12-Year High Following Favorable Midstage Study Results Benzinga
01:10PM  2 Rallying Pharma Stocks Roping In Option Bulls Schaeffer's Investment Research
12:37PM  Here's Why ArQule Is Soaring Again Today Motley Fool
09:31AM  Company News For Jun 17, 2019 Zacks
09:00AM  ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference Business Wire
Jun-15-19 12:38PM  The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-14-19 01:18PM  ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results InvestorPlace +30.37%
12:56PM  A Look At Benzinga Pro's Most-Searched Tickers For June 14 Benzinga
11:52AM  Here's Why ArQule Shares Rose as Much as 44.7% Today Motley Fool
10:31AM  ArQule Jumps on Positive Phase 1 Blood Cancer Trial Results TheStreet.com
09:47AM  Why Small-Cap Biotech ArQule Is Rallying Benzinga
09:05AM  Stock Market News: Chewy Goes Public; ArQule Soars on Cancer Study Motley Fool
08:57AM  ArQule stock rockets 49% toward 12-year high after biotech announces Phase 1 trial results MarketWatch
08:47AM  The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA Benzinga
03:30AM  ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting Business Wire
Jun-10-19 11:12AM  Imagine Holding ArQule (NASDAQ:ARQL) Shares While The Price Zoomed 346% Higher Simply Wall St.
07:00AM  ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference Business Wire
Jun-07-19 07:00AM  ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA) Business Wire
May-30-19 07:00AM  ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019 Business Wire
May-22-19 01:47PM  Harry Boxers three stocks to watch include Roku MarketWatch
01:36PM  The Tech Trader's 3 Stocks On The Move Benzinga
May-15-19 07:00AM  ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 Business Wire
May-14-19 07:00AM  ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019 Business Wire
May-08-19 07:00AM  ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019 Business Wire
May-04-19 11:14PM  Edited Transcript of ARQL earnings conference call or presentation 1-May-19 1:00pm GMT Thomson Reuters StreetEvents
May-01-19 05:37PM  Arqule Inc (ARQL) Q1 2019 Earnings Call Transcript Motley Fool +6.37%
01:40PM  Here's Why ArQule Rose as Much as 12.7% Today Motley Fool
08:45AM  ArQule (ARQL) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:42AM  ArQule: 1Q Earnings Snapshot Associated Press
07:39AM  The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue Benzinga
07:00AM  ArQule Reports First Quarter 2019 Financial Results Business Wire
Apr-30-19 04:01PM  Sinovant Sciences Announces Approval of Derazantinibs Clinical Trial Application by the China National Medical Products Administration Business Wire
Apr-24-19 10:33AM  Analysts Estimate ArQule (ARQL) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-21-19 09:02AM  ArQule, Inc. (NASDAQ:ARQL) Insiders Increased Their Holdings Simply Wall St.
Apr-17-19 04:01PM  ArQule to Report First Quarter 2019 Financial Results on May 1, 2019 Business Wire
Apr-11-19 08:39AM  Do Options Traders Know Something About ArQule (ARQL) Stock We Don't? Zacks
Apr-02-19 07:00AM  ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019 Business Wire
Mar-15-19 07:00AM  ArQule Announces Management Team Changes Business Wire
Mar-13-19 09:52AM  Edited Transcript of ARQL earnings conference call or presentation 7-Mar-19 2:00pm GMT Thomson Reuters StreetEvents
07:00AM  ArQule to Present at Oppenheimers 29th Annual Healthcare Conference on March 20, 2019 Business Wire
Mar-11-19 07:00AM  ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019 Business Wire
Mar-09-19 12:09PM  Can Arqule Stock Continue Rocketing Higher? Motley Fool
Mar-07-19 04:30PM  Why Rosetta Stone, ArQule, and Fly Leasing Jumped Today Motley Fool +67.38%
03:37PM  Arqule Inc (ARQL) Q4 2018 Earnings Conference Call Transcript Motley Fool
01:35PM  Here's Why ArQule Is Soaring Today Motley Fool
07:00AM  ArQule Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
Mar-06-19 01:32PM  Is ArQule, Inc.s (NASDAQ:ARQL) CEO Paid At A Competitive Rate? Simply Wall St. -9.72%
Feb-26-19 07:45AM  Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A New Research Emphasizes Economic Growth GlobeNewswire
Feb-25-19 07:00AM  ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome Business Wire +6.59%
Feb-21-19 07:00AM  ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019 Business Wire
07:00AM  ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019 Business Wire
Jan-24-19 07:00AM  Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer Business Wire
Jan-22-19 04:00PM  Penny Stocks to Buy Using Technical Analysis for January 2019 Investopedia
Jan-09-19 07:00AM  Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA) Business Wire +5.18%
Jan-07-19 08:32AM  What You Must Know About ArQule, Inc.s (NASDAQ:ARQL) Beta Value Simply Wall St. +9.40%
Dec-26-18 01:20PM  4 Pharma Stocks Heating Up On Wednesday (12/26/18) ACCESSWIRE +15.70%
07:30AM  Biotech News Driving These Companies ACCESSWIRE
07:25AM  Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-24-18 08:58AM  Options Traders Expect Huge Moves in ArQule (ARQL) Stock Zacks +7.08%
Dec-19-18 07:00AM  ArQule Added to the NASDAQ Biotechnology Index Business Wire
Dec-12-18 12:52AM  ArQule, Inc. (ARQL): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-03-18 07:00AM  ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting Business Wire
Dec-02-18 05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
Nov-29-18 07:35AM  Recent Analysis Shows HudBay Minerals, Meridian Bioscience, ArQule, Mesoblast, Concho Resources, and Liberty Global Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +5.48%
07:00AM  ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies Business Wire
Nov-21-18 10:57AM  Could ArQule Incs (NASDAQ:ARQL) Investor Composition Influence The Stock Price? Simply Wall St.
Nov-19-18 07:00AM  ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting Business Wire -7.75%
Nov-16-18 04:01PM  ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium Business Wire
08:46AM  Options Traders Expect Huge Moves in ArQule (ARQL) Stock Zacks
08:08AM  The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal Benzinga
Nov-14-18 07:00AM  ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018 Business Wire
Nov-12-18 05:46PM  Edited Transcript of ARQL earnings conference call or presentation 31-Oct-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-08-18 07:00AM  ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium Business Wire
Nov-01-18 02:47AM  ArQule (ARQL) Q3 2018 Earnings Conference Call Transcript Motley Fool
Oct-31-18 08:15AM  ArQule (ARQL) Reports Q3 Loss, Tops Revenue Estimates Zacks -7.64%
07:08AM  ArQule: 3Q Earnings Snapshot Associated Press
07:00AM  ArQule Reports Third Quarter 2018 Financial Results Business Wire
Oct-19-18 08:40AM  New Research Coverage Highlights TIER REIT, Meridian Bioscience, ArQule, Greenlight Capital Re, ADT, and Turquoise Hill Resources Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire -8.09%
07:00AM  ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092) Business Wire
Oct-17-18 08:15AM  The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise Benzinga
07:00AM  ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018 Business Wire
Oct-14-18 01:21PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Oct-04-18 04:01PM  ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics (ASHG) 2018 Annual Meeting Business Wire -9.11%
Sep-24-18 07:00AM  ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018 Business Wire
07:00AM  ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018 Business Wire
Sep-19-18 01:11PM  ArQule Inc (NASDAQ:ARQL) Is Expected To Breakeven Simply Wall St.
Sep-13-18 07:00AM  Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS) Business Wire
Sep-05-18 08:52AM  Implied Volatility Surging for ArQule (ARQL) Stock Options Zacks
Aug-30-18 04:01PM  ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018 Business Wire
04:01PM  ArQule to Participate in Citis 13th Annual Biotech Conference on September 6, 2018 Business Wire
Aug-29-18 04:01PM  ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018 Business Wire
Aug-21-18 07:40AM  Analysis: Positioning to Benefit within PagSeguro Digital, ChannelAdvisor, Transocean, Arcos Dorados, Precision Drilling, and ArQule Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.46%
Aug-13-18 04:01PM  ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK Business Wire
Aug-02-18 11:29AM  Edited Transcript of ARQL earnings conference call or presentation 1-Aug-18 1:00pm GMT Thomson Reuters StreetEvents
Aug-01-18 01:55PM  Here's Why ArQule Inc. Rose as Much as 20.1% Today Motley Fool +14.46%
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHEGERIN MARCChief Financial OfficerJun 06Option Exercise2.5210,00025,20013,039Jun 10 01:33 PM
LINDSAY RONALD MDirectorApr 15Option Exercise3.8710,00038,70060,800Apr 16 12:28 PM
LOBERG MICHAEL DDirectorApr 10Option Exercise3.8710,00038,700172,514Apr 11 12:12 PM
Messenger William GDirectorApr 09Option Exercise3.8710,00038,70020,000Apr 11 12:22 PM
ZENNER PATRICK JDirectorApr 05Option Exercise3.8715,00058,05097,216Apr 08 04:58 PM
BARABE TIMOTHY CDirectorApr 04Option Exercise3.8710,00038,700146,897Apr 08 04:17 PM
Pucci PaoloChief Executive OfficerMar 15Option Exercise1.1650,00058,000618,208Mar 18 03:41 PM
Nussbaum RanDirectorJul 13Buy5.50181,818999,9993,348,676Oct 22 02:54 PM